Register entry

Vanda Pharmaceuticals Inc.

Registered sites
0
Drug products
38
Live patents
259
Countries
0
Base
Unknown
Sites

Facilities

0

No registered facilities

This company holds drug listings or approvals but operates no registered establishment of its own, which is normal for an NDA holder that outsources manufacturing.

Exclusivity

Patents

259

Unexpired Orange Book patents where this company is the application holder.

ProductActive ingredientExpiry
BYSANTIMILSAPERIDONEMar 2028
BYSANTIMILSAPERIDONEApr 2030
BYSANTIMILSAPERIDONEJul 2030
BYSANTIMILSAPERIDONESept 2030
BYSANTIMILSAPERIDONEOct 2030
BYSANTIMILSAPERIDONEDec 2030
BYSANTIMILSAPERIDONEJan 2031
BYSANTIMILSAPERIDONEFeb 2031
BYSANTIMILSAPERIDONEDec 2031
BYSANTIMILSAPERIDONEMay 2044
FANAPTILOPERIDONENov 2027
FANAPTILOPERIDONEMar 2028
FANAPTILOPERIDONEApr 2030
FANAPTILOPERIDONEJul 2030
FANAPTILOPERIDONEAug 2030
FANAPTILOPERIDONESept 2030
FANAPTILOPERIDONEOct 2030
FANAPTILOPERIDONEDec 2030
FANAPTILOPERIDONEJan 2031
FANAPTILOPERIDONEFeb 2031
FANAPTILOPERIDONEDec 2031
HETLIOZTASIMELTEONJan 2033
HETLIOZTASIMELTEONApr 2033
HETLIOZTASIMELTEONMay 2034
HETLIOZTASIMELTEONOct 2034
HETLIOZTASIMELTEONFeb 2035
HETLIOZTASIMELTEONJul 2035
HETLIOZTASIMELTEONAug 2035
HETLIOZTASIMELTEONFeb 2041
HETLIOZ LQTASIMELTEONJan 2033
HETLIOZ LQTASIMELTEONApr 2033
HETLIOZ LQTASIMELTEONMay 2034
HETLIOZ LQTASIMELTEONOct 2034
HETLIOZ LQTASIMELTEONFeb 2035
HETLIOZ LQTASIMELTEONJul 2035
HETLIOZ LQTASIMELTEONAug 2035
HETLIOZ LQTASIMELTEONDec 2040
HETLIOZ LQTASIMELTEONFeb 2041
NEREUSTRADIPITANTMar 2036
NEREUSTRADIPITANTAug 2036
PONVORYPONESIMODNov 2029
PONVORYPONESIMODMay 2032
PONVORYPONESIMODDec 2035
PONVORYPONESIMODOct 2042
Catalogue

Marketed products

38

Showing 38 of 38.

BrandGeneric nameFormCategory
BYSANTIMILSAPERIDONETABLETNDA
BYSANTIMILSAPERIDONETABLETNDA
BYSANTIMILSAPERIDONETABLETNDA
BYSANTIMILSAPERIDONETABLETNDA
BYSANTIMILSAPERIDONETABLETNDA
BYSANTIMILSAPERIDONETABLETNDA
BYSANTIMILSAPERIDONETABLETNDA
BYSANTIMILSAPERIDONEKITNDA
BYSANTIMILSAPERIDONEKITNDA
BYSANTIMILSAPERIDONEKITNDA
BYSANTIMILSAPERIDONETABLETNDA
BYSANTIMILSAPERIDONETABLETNDA
BYSANTIMILSAPERIDONETABLETNDA
BYSANTIMILSAPERIDONEKITNDA
BYSANTIMILSAPERIDONEKITNDA
BYSANTIMILSAPERIDONEKITNDA
FANAPTILOPERIDONETABLETNDA
FANAPTILOPERIDONETABLETNDA
FANAPTILOPERIDONETABLETNDA
FANAPTILOPERIDONETABLETNDA
FANAPTILOPERIDONETABLETNDA
FANAPTILOPERIDONETABLETNDA
FANAPTILOPERIDONETABLETNDA
FANAPTILOPERIDONEKITNDA
FANAPTILOPERIDONEKITNDA
FANAPTILOPERIDONEKITNDA
FANAPTILOPERIDONETABLETNDA
FANAPTILOPERIDONETABLETNDA
FANAPTILOPERIDONEKITNDA
FANAPTILOPERIDONETABLETNDA
FANAPTILOPERIDONETABLETNDA
FANAPTILOPERIDONEKITNDA
FANAPTILOPERIDONEKITNDA
HetlioztasimelteonCAPSULENDA
Hetlioz LQtasimelteonSUSPENSIONNDA
NEREUSTRADIPITANTCAPSULENDA
PONVORYPonesimodKITNDA
PONVORYPonesimodTABLET, FILM COATEDNDA
Provenance

Facility and operations data from the FDA Drug Establishments Current Registration Site. Product data from the openFDA National Drug Code Directory. Patent and exclusivity data from the FDA Orange Book. Shortage data from the FDA drug shortage database. Contact details the FDA publishes for registered establishments are deliberately not reproduced here. This entry is compiled from public records and has not been claimed by the company.